Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of Neu-P12 in healthy male volunteers
NL-OMON45352Phase 1Active, not recruiting
- Sponsor
- QPS
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain and pruritus comparing Neu-P12 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Feb 2017; status: active, not recruiting.
02
Drugs
Neu-P12
03
Conditions
painpruritus
Beyond the preview
Go deeper on NL-OMON45352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45352.